Oppenheimer Asset Management Inc. lowered its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 22.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 197,199 shares of the company's stock after selling 56,430 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Takeda Pharmaceutical were worth $2,804,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of the business. EverSource Wealth Advisors LLC grew its holdings in Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company's stock valued at $43,000 after buying an additional 859 shares in the last quarter. Hexagon Capital Partners LLC increased its holdings in Takeda Pharmaceutical by 34.3% during the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company's stock worth $63,000 after acquiring an additional 1,129 shares during the period. Headlands Technologies LLC purchased a new stake in Takeda Pharmaceutical in the 2nd quarter worth approximately $59,000. Blue Trust Inc. boosted its holdings in Takeda Pharmaceutical by 74.0% in the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company's stock valued at $76,000 after purchasing an additional 2,330 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Takeda Pharmaceutical by 136.1% during the 3rd quarter. GAMMA Investing LLC now owns 6,295 shares of the company's stock valued at $90,000 after purchasing an additional 3,629 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.
Takeda Pharmaceutical Price Performance
Shares of Takeda Pharmaceutical stock traded up $0.05 during trading on Friday, hitting $13.62. The stock had a trading volume of 2,197,155 shares, compared to its average volume of 1,295,458. The firm has a market cap of $43.34 billion, a price-to-earnings ratio of 23.48, a P/E/G ratio of 0.26 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The business's 50-day moving average is $14.24 and its 200 day moving average is $13.83. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64.
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Stories
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
